---
title: "Novo Nordisk's Head of Product and Portfolio Strategy, Helgoet: Compared to competitor Eli Lilly's w"
description: "Novo Nordisk's Head of Product and Portfolio Strategy, Helgoet: Compared to competitor Eli Lilly's weight loss medication, oral semaglutide has very attractive advantages"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/257694839.md"
published_at: "2025-09-17T09:39:30.000Z"
---

# Novo Nordisk's Head of Product and Portfolio Strategy, Helgoet: Compared to competitor Eli Lilly's w

> Novo Nordisk's Head of Product and Portfolio Strategy, Helgoet: Compared to competitor Eli Lilly's weight loss medication, oral semaglutide has very attractive advantages

Novo Nordisk's Head of Product and Investment Portfolio Strategy, Helgot: Compared to competitor Eli Lilly's weight loss medication, oral semaglutide has very attractive advantages

### Related Stocks

- [NVO.US - Novo Nordisk AS](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Puzo Michael J Has $320,000 Stock Position in Novo Nordisk A/S $NVO | Puzo Michael J significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) by 86.9% in Q3, now holding 5,775 shares v | [Link](https://longbridge.com/en/news/276447697.md) |
| Novo Nordisk Proposes Two Additional New Board Appointments | Danish pharmaceutical company Novo Nordisk is proposing three new appointments to its board of directors for the annual  | [Link](https://longbridge.com/en/news/276442777.md) |
| GLP-1 Anti-Obesity U.S. Drug Market In Four Charts | UBS analysts, led by Matthew Weston, have analyzed trends in the U.S. GLP-1 anti-obesity drug market, focusing on new-to | [Link](https://longbridge.com/en/news/276280378.md) |
| Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair | [Link](https://longbridge.com/en/news/276440991.md) |
| Novo Nordisk: Will Have Replacements for Ozempic and Wegovy Ready When Patents Expire - Berlingske | Danish pharmaceutical company Novo Nordisk plans to have replacement drugs ready for Ozempic and Wegovy when their paten | [Link](https://longbridge.com/en/news/276314777.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.